Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.

导出 OA

翻译打印收藏纠错

第一作者： Kimball A,Johnson

第一单位： iResearch Atlanta, LLC, Decatur, Georgia 30030, USA.

作者： Kimball A,Johnson ^[1] ; Nancy,Martin ^[2] ; Rossella E,Nappi ^[3] ; Genevieve,Neal-Perry ^[4] ; Marla,Shapiro ^[5] ; Petra,Stute ^[6] ; Rebecca C,Thurston ^[7] ; Wendy,Wolfman ^[8] ; Marci,English ^[9] ; Catherine,Franklin ^[2] ; Misun,Lee ^[10] ; Nanette,Santoro ^[11]

作者单位： iResearch Atlanta, LLC, Decatur, Georgia 30030, USA. ^[1] Employee of Astellas Pharma Global Development at the Time of the Study, Northbrook, IL, USA. ^[2] Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, and Research Center for Reproductive Medicine and Gynecological Endocrinology - Menopause Unit, Fondazione Policlinico IRCCS S. Matteo, Pavia 27100, Italy. ^[3] Department of Obstetrics and Gynecology, UNC School of Medicine, Chapel Hill, NC 27599, USA. ^[4] Department of Family and Community Medicine, University of Toronto, Toronto, Ontario M5S 1A1, Canada. ^[5] Department of Obstetrics and Gynecology, Inselspital, Bern CH-3010, Switzerland. ^[6] Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. ^[7] Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario M5G 1E2, Canada. ^[8] Global Development, Astellas Pharma Global Development, Inc., Northbrook, IL 60062, USA. ^[9] Biostatistics, Astellas Pharma Global Development, Inc., Northbrook, IL 60062, USA. ^[10] Division of Reproductive Sciences, University of Colorado School of Medicine, Aurora, CO 80045, USA. ^[11]

关键词 KNDy fezolinetant neurokinin 3 receptor antagonist nonhormonal vasomotor symptoms

主题词女(雌)性(Female);人类(Humans);热潮红(Hot Flashes);治疗结果(Treatment Outcome);绝经期(Menopause);双盲法(Double-Blind Method)

DOI 10.1210/clinem/dgad058

PMID 36734148

发布时间 2024-07-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交